MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.
Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term, appointed KPMG LLP as the Company’s auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries.
All candidates proposed for the position of director were elected in the following proportion:
| FOR | % FOR | ABSTENTION | % ABSTENTION | |
| Joseph Arena | 20,473,944 | 84.03% | 3,890,222 | 15.97% |
| Frank Holler | 19,089,786 | 78.35% | 5,274,380 | 21.65% |
| Paul Lévesque | 19,027,772 | 78.10% | 5,336,394 | 21.90% |
| Andrew Molson | 19,066,145 | 78.25% | 5,298,021 | 21.75% |
| Dawn Svoronos | 18,998,230 | 77.98% | 5,365,936 | 22.02% |
| Elina Tea | 19,163,502 | 78.65% | 5,200,664 | 21.35% |
| Dale Weil | 19,005,768 | 78.01% | 5,358,398 | 21.99% |
| Jordan Zwick | 19,618,725 | 80.52% | 4,745,441 | 19.48% |
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
514-336-7800
| Last Trade: | US$3.25 |
| Daily Change: | 0.01 0.31 |
| Daily Volume: | 973,450 |
| Market Cap: | US$149.440M |
July 02, 2025 April 09, 2025 April 08, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
